No Detail Found!

Novel Inflammatory Biomarkers in Patients with Mycosis Fungoides Treated with Bexarotene

Author(s)
Funda Tamer Department of Dermatology, Gazi University School of Medicine,Ankara,Turkey
Ayla Gulekon Department of Dermatology, Gazi University School of Medicine,Ankara,Turkey
Abstract
Mycosis fungoides (MF) is a skin lymphoma characterised by atypical T lymphocyte in ltration, which may present with patches and tumors in advanced stages. Treatment options in MF aim to reduce symptoms, since patients usually do not achieve complete cure. Bexarotene is used for treatment-resistant early stage MF and advanced stages of the disease. It has been suggested that white blood cell (WBC)/absolute lymphocyte count, WBC, absolute lymphocyte and eosinophil counts might be prognostic factors in MF. Therefore, we investigated the changes in complete blood count (CBC) parameters and CBC-derived in ammatory biomarkers in patients with MF treated with bexarotene. The results revealed that neutrophil (NE)%, NE numbers, neutrophil/lymphocyte, derived neutrophil/lymphocyte, (neutrophil × monocytes)/lymphocyte and (neutrophils × monocytes × platelets)/lymphocyte counts decreased in all patients three months after bexarotene treatment. We suggest that these in ammatory biomarkers can be used in the follow-up of patients with MF receiving bexarotene treatment. Moreover, these results indicate that decrease in these in ammatory biomarkers may signify improvement of the disease.
Publication Details
Page(s) 716-718
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 31, Issue: 6, Year: 2021

Request the full text from PASTIC

Keywords
Mycosis fungoides, 0n ammatory biomarkers, Bexarotene
0

Citations

0

Downloads

49

Views